文献速递血栓与止血

急性癌症相关静脉血栓栓塞患者抗凝药与缺血性卒中风险的比较

Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism.
PubMed 文献 · Blood Adv · 2026-01-01

本研究为回顾性、基于人群的队列研究,利用监测、流行病学和最终结果数据链接医疗保险理赔数据,纳入2007至2015年诊断原发性脑、结直肠、胃、胰腺、肺或卵巢癌且诊断为静脉血栓栓塞并接受直接口服抗凝药、低分子肝素或华法林处方的患者,按倾向评分1:1:1匹配为三组,每组1625例,共4875例。主要比较6个月缺血性卒中累积发生率,总体为5.6%(95%CI 5.0-6.3),直接口服抗凝药组6.8%(95%CI 5.6-8.1),低分子肝素组4.9%(95%CI 3.9-6.0),华法林组5.2%(95%CI 4.1-6.2),P=0.040。多变量模型显示高血压(OR 1.75)、心房颤动/扑动(OR 1.37)、直接口服抗凝药使用(OR 1.36)和既往卒中(OR 3.59)为缺血性卒中的统计学显著危险因素。结论认为缺血性卒中在癌症相关静脉血栓栓塞后常见,直接口服抗凝药治疗者可能更频繁发生。

要点

  • 6个月缺血性卒中累积发生率总体5.6%,直接口服抗凝药组6.8%、低分子肝素组4.9%、华法林组5.2%(P=0.040)。
  • 多变量模型中缺血性卒中显著危险因素:高血压OR 1.75、心房颤动/扑动OR 1.37、直接口服抗凝药使用OR 1.36、既往卒中OR 3.59。
  • 结论认为缺血性卒中在癌症相关静脉血栓栓塞后常见,直接口服抗凝药治疗者可能更频繁发生。

核心结论

  • 缺血性卒中在癌症相关静脉血栓栓塞后常见,直接口服抗凝药治疗者可能更频繁发生。

研究设计与样本

  • 回顾性、基于人群的队列研究,使用监测、流行病学和最终结果数据链接医疗保险理赔数据。
  • 纳入2007至2015年诊断原发性脑、结直肠、胃、胰腺、肺或卵巢癌、诊断为静脉血栓栓塞且有直接口服抗凝药、低分子肝素或华法林处方理赔的患者。
  • 按基线人口学信息、癌症特异性特征和心血管合并症进行倾向评分1:1:1匹配,共4875例,每组1625例。

主要发现

  • 6个月缺血性卒中累积发生率总体为5.6%(95%CI 5.0-6.3)。
  • 直接口服抗凝药组6个月累积发生率为6.8%(95%CI 5.6-8.1),低分子肝素组为4.9%(95%CI 3.9-6.0),华法林组为5.2%(95%CI 4.1-6.2),P=0.040。
  • 多变量模型显示高血压(OR 1.75)、心房颤动/扑动(OR 1.37)、直接口服抗凝药使用(OR 1.36)和既往卒中(OR 3.59)为缺血性卒中的统计学显著危险因素。

关键数值与推荐

  • 6个月缺血性卒中累积发生率:总体5.6%(95%CI 5.0-6.3),直接口服抗凝药组6.8%(95%CI 5.6-8.1),低分子肝素组4.9%(95%CI 3.9-6.0),华法林组5.2%(95%CI 4.1-6.2),P=0.040。
  • 缺血性卒中危险因素:高血压OR 1.75,心房颤动/扑动OR 1.37,直接口服抗凝药使用OR 1.36,既往卒中OR 3.59。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is a frequent occurrence in patients with cancer. However, it is not known whether treatment with different classes of anticoagulants impacts the risk of subsequent arterial thromboembolism. We performed a retrospective, population-based cohort study using Surveillance, Epidemiology, and End Results data linked with Medicare claims. Patients were eligible for study inclusion if they had a diagnosis of primary brain, colorectal, gastric, pancreatic, lung, or ovarian cancer between 2007 and 2015, were diagnosed with VTE, and had a prescription claim for a direct oral anticoagulant (DOAC), low-molecular-weight heparin (LMWH), or warfarin. We matched patients by propensity score in a 1:1:1 ratio into anticoagulant treatment groups based on their baseline demographic information, cancer-specific characteristics, and cardiovascular comorbidities. The primary aim of the study was to determine and compare the 6-month cumulative incidence of ischemic stroke across anticoagulant classes. The study comprised 4875 total patients with 1625 in each treatment group. At 6 months, the cumulative incidence of ischemic stroke was 5.6% (95% confidence interval [CI], 5.0-6.3) overall and 6.8% (95% CI, 5.6-8.1) in the DOAC, 4.9% (95% CI, 3.9-6.0) in the LMWH, and 5.2% (95% CI, 4.1-6.2) in the warfarin treatment groups (P = .040). We identified hypertension (odds ratio [OR], 1.75), atrial fibrillation/flutter (OR, 1.37), DOAC use (OR, 1.36), and previous stroke (OR, 3.59) as statistically significant risk factors for ischemic stroke in the multivariable modeling. In conclusion, ischemic stroke is a common occurrence after cancer-associated VTE and may occur more frequently in patients treated with DOACs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ma S, Chang YC, Chiang CH, et al. Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism. Blood Adv. 2026. PMID: 40845270. doi:10.1182/bloodadvances.2025017523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。